Search This Blog

Sunday, May 12, 2024

'Biden just quietly took a key step to ‘decriminalize’ traffic safety policy'

 The Biden administration recently took a crucial but little-noticed step to improve public safety: it ended a deeply flawed policing program that encouraged law enforcement nationwide to use traffic stops as a pretext for fighting crime.

It must now ensure that what comes next is a step forward.

The program, Data-Driven Approaches to Crime and Traffic Safety (DDACTS), was based on the idea that by pulling over more drivers in “high crime” areas, even for minor infractions like broken taillights, police could reduce both traffic crashes and street crime simultaneously.

It sounds like a clever way to fight crime and promote traffic safety. The only problem is that it does neither.

Study after study has found no clear link between aggressive traffic enforcement and reduced crime rates. This should not come as a surprise, because the people being stopped were never suspected of criminal activity.

In Nashville, a city that at one time championed this approach, researchers found no relationship between the number of police stops and crime levels. And when Fayetteville, N.C. scaled back stops for minor violations, traffic accidents actually fell, presumably because police had more time to focus on genuine safety-related stops.

What these programs have done is erode trust, violate civil liberties, and make roads more dangerous for Black drivers. In Nashville, Black drivers were 68 percent more likely to be pulled over for non-moving violations. As the killing of Tyre Nichols tragically underscores, these stops can escalate into violence and even death at the hands of police.

The harms inflicted and risks posed by programs like DDACTS are the reason more than seventy transportation safety and civil rights organizations joined my colleagues at the Policing Project in demanding an end to the program. It’s also why the NAACP Legal Defense Foundation wrote that initiatives like it should “neither be tolerated nor encouraged.”

Ending federal support for DDACTS was a necessary corrective, but it’s just the beginning of a broader reckoning that is needed with American traffic enforcement. In fact, there are many programs like DDACTS that should be reassessed. High-volume traffic enforcement has become a back door for discriminatory over-policing, and one that, evidence shows, neither fights crime nor makes our roads safer.

The way to fight crime is not with stops based on hunches and pretext, but by investing proactively in communities and with policing targeted at people for whom there is suspicion of serious criminal conduct.

On the other hand, there is a real traffic safety problem in this country. According to the U.S. Department of Transportation, more than 350,000 people have died from crashes on American roads in the last decade. More than 44,000 people were killed in car crashes in 2023 alone. That problem needs to be addressed, urgently.

It is time we returned to proven methods of addressing the traffic safety epidemic. We know that redesigning streets and improving vehicle safety standards can save lives and prevent traffic accidents and injuries. That is where transportation officials should focus their efforts. We need to dramatically increase investment in evidence-based strategies that are proven to save lives: for example, by designing safer roads with better lighting; creating protected bike lanes and pedestrian crossings; requiring automakers to incorporate advanced safety features; and expanding access to reliable, affordable public transportation.

We also must invest more in rigorous research. For too long, traffic enforcement policies have been based on assumptions rather than evidence. We need high-quality studies that examine not just crash and crime rates, but also whether and to what extent enforcement works to reduce traffic accidents.

We should also explore the value of automated traffic enforcement, such as speed cameras with fines scaled to income. These studies should also take into account the social costs they impose on those stopped, such as whether the fines are prohibitive for those living paycheck to paycheck. And above all, we should be listening to community voices about how to improve traffic safety.

The role of traffic enforcement should be focused narrowly on the most dangerous driving behaviors, guided by data and observable safety hazards rather than hunches and pretext. It should be based on empirical evidence on the value of enforcement. It is also worth asking whether armed police are necessary for ordinary traffic enforcement.

Transforming our approach to traffic enforcement is no small undertaking. But it is a necessary one if we want a future where our roads are safe, just, and equitable for all. The end of DDACTS should be a turning point — the moment when we begin to disentangle the contradictory imperatives of crime reduction and traffic safety and chart a new vision for public safety on America’s streets. We should be pursuing policies proven to work, rather than seeking easy answers with discriminatory over-enforcement.

Farhang Heydari is an assistant professor of law at Vanderbilt University Law School and a senior advisor to the Policing Project.

https://thehill.com/opinion/criminal-justice/4653862-biden-just-quietly-took-a-key-step-to-decriminalize-traffic-safety/

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

 Leading healthcare companies Pfizer (NYSE:PFE) and AstraZeneca (NASDAQ:AZN) announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Pfizer said it would invest 500 million euros ($538.5 million) in France to build up its research and development work in the country, while AstraZeneca announced an investment of $388 million for its site at Dunkirk.

Their investment pledges came as President Emmanuel Macron prepared to kick off on Monday the annual 'Choose France' event aimed at wooing big overseas businesses and investors.

France announced earlier on Sunday 100 new jobs in Paris at Wall Street bank Morgan Stanley, and investments from other firms such as German aviation company Lilium.

Macron wants to burnish Paris' role as a top European business capital, although it has traditionally lagged New York and London on a global scale.

The closely watched Z/Yen survey of global financial centres, published in March, ranked New York as the world's top financial centre, with London in second place. The survey ranked Paris in 14th position.

https://www.investing.com/news/stock-market-news/pfizer-and-astrazeneca-announce-new-investments-of-nearly-1-billion-in-france-3435954

Cell and Gene Therapies Still Have Long Way to Go in Fulfilling Promise

 The 2024 American Society of Gene & Cell Therapy annual meeting attracted a record number of attendees and abstracts, testimony to the tremendous growth of the cell and gene therapy industry. But for me, my week onsite in Baltimore laid bare the major challenges that stand between cell and gene therapies (CGTs) and the masses.

To be sure, the CGT space has come a long way in a very short time, with a record seven approvals in 2023, and this year looking to bring even more therapies to market. The commercial side of this space is particularly apparent now as the race between Vertex Pharmaceuticals’ CRISPR-based Casgevy and bluebird bio’s gene therapy Lyfgenia heats up.

And there were some amazing technologies in the spotlight at ASGCT 2024, with several major advancements poised to transform the sector. Particularly noteworthy were new advancements in gene editing. While the CRISPR genome editing platform earned the Nobel Prize in 2020, the technology has limitations and risks, and researchers are looking to develop more accurate and safe DNA editors.

One example is Prime Medicine, which showcased its prime editing technology at ASGCT 2024 after receiving FDA clearance recently for a first clinical study. The company contends that prime editors, which can rewrite defective genes without breaking both strands of the DNA double helix, have the capability to repair almost all types of genetic mutations while avoiding the risk of harmful side effects. Prime Medicine also argued that its technology works in many different tissues, organs and cell types, with opportunities across thousands of indications.

Another leap in the CGT space is in engineered cell therapies, which seem to be entering a second revolution, the first being the commercialization of CAR-T cell therapies.

However, Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, provided a sobering assessment at ASGCT 2024 of the opportunities and challenges facing the industry. Marks said that it’s “quite an exciting time” for gene therapies in the U.S. with 20 indications and 19 products approved but emphasized there are “some real challenges” including manufacturing, clinical development timelines and different global regulatory requirements.

“We are at a critical juncture," Marks, the FDA’s top biologics regulator, said. “We see products dropping out of development because they’re simply not felt to be commercially viable,” particularly for rare diseases.

ASGCT 2024 fostered a lot of good conversations about the regulatory hurdles facing the CGT industry. However, just as important were the discussions around the significant manufacturing challenges confronting the sector.

Marks touted the progress of the Bespoke Gene Therapy Consortium (BGTC), a public-private collaboration involving the National Institutes of Health, FDA, industry and patient groups intended to help accelerate the delivery of AAV-based gene therapies for rare diseases. And in one standing room-only session this week, representatives from several biopharma companies presented on their work to improve the efficiency and quality of AAV production.

At the same time, it should also be remembered that ASGCT 2024 kicked off with the sad news that a young boy with Duchenne muscular dystrophy (DMD) in Pfizer’s Phase II gene therapy trial died, causing the company to pause dosing. In 2021, a Phase Ib DMD study was similarly halted by Pfizer after an unexpected patient death.

On Thursday, I attended a Pfizer event in the exhibit hall. After the formal remarks and before Q&A began, a company spokesperson took the podium and said they would not be able to answer any questions regarding the death of the boy in the trial. “There’s no further information that we have to share at this time, and we’re in the process of gathering additional information.”

Ironically, Pfizer’s presentation in the exhibit hall was entitled “Progress and Challenges in Genetic Medicine” and included a discussion about “the importance of careful patient selection for clinical trials.”

The death in the latest Pfizer DMD trial is still being investigated and no cause has been established. However, we were reminded this week how far the industry still needs to go, despite the fact advancements are increasingly making these technologies a therapeutic reality.

With ASGCT 2024 winding down, I can say I learned a lot about the state of the CGT industry—both positive and negative—in the sessions and networking opportunities at the annual meeting. I’m looking forward to ASGCT 2025 in New Orleans. Hopefully by then, we’ll see significant progress in addressing some of these challenges. 

https://www.biospace.com/article/cell-and-gene-therapies-still-have-long-way-to-go-in-fulfilling-promise/

Saturday, May 11, 2024

Neuralink Rival Backed By Bezos, Gates Broadens Plans To Treat Parkinson's, Epilepsy

 Synchron Inc., a competitor to Elon Musk‘s Neuralink Corp. backed by Jeff Bezos and Bill Gates, has revealed plans to extend its brain-device technology to treat conditions such as epilepsy and Parkinson’s disease.

What Happened: On Thursday at the Bloomberg Tech Summit, Synchron’s founder, Tom Oxley, disclosed the company’s expansion strategy saying that it intends to adapt its existing device, the Stentrode, for these new treatments, reported Bloomberg

Oxley stated that the company intends to initiate a review by the U.S. Food and Drug Administration for its Parkinson's and epilepsy treatment, but refrained from specifying the timeline.

Unlike Neuralink, Synchron’s approach does not require brain surgery. The Stentrode is implanted into a vein in the neck, and blood vessels transport it to the top of the brain’s motor cortex. Patients can then use the device to control external tools, such as computer cursors, using their thoughts.

The Stentrode is currently implanted in a small number of U.S. patients and is in the early feasibility stage of the review process.

Why It Matters: This development comes on the heels of a milestone for Neuralink. Just a day before Synchron’s announcement, Musk celebrated the successful 100-day milestone since the first human implant of Neuralink’s brain-computer interface (BCI). However, the company also acknowledged a malfunction in the system.

Noland Arbaughthe first participant, underwent the implant procedure at the Barrow Neurological Institute in Phoenix, Arizona. Following a successful surgery, Arbaugh was discharged the next day. However, Neuralink has now disclosed that a portion of the implant experienced malfunctioning post-surgery.

Meanwhile, Synchron had announced its plans to challenge Neuralink with an upcoming large-scale brain implant trial. Last month, it was reported that the company was advancing toward a pivotal clinical trial for its innovative brain implant technology.

https://www.benzinga.com/general/biotech/24/05/38751782/neuralink-rival-backed-by-jeff-bezos-and-bill-gates-broaden-horizons-with-plans-to-treat-parkinso

Why Russia Is Making A Fresh Push Into Ukraine's Kharkov Region

 By Andrew Korybko of the Korybko substack

The five objectives that are enumerated in this piece encapsulate what Russia nowadays aims to achieve after over two years of intense proxy warfare with NATO.

Zelensky claimed on Friday that Russia’s long-awaited offensive had finally begun following its fresh push into Kharkov Region from which it tactically pulled back in September 2022. This precedes him likely clinging to power on legally dubious pretexts once his term expires on 21 May and aligns with the Ukrainian Intelligence Committee’s prediction of political-military troubles heading into his summer.

Here are the five objectives that Russia arguably aims to achieve in view of the conflict’s larger context:

1. Create The Conditions For Russia To Control The Entirety Of Its New Regions

Russia’s increasingly frequent gains in Donbass over the past month speak to how serious Ukraine’s conscription and logistical crises have become, thus enabling Moscow to push them to the breaking point by opening up a new front at this precise moment in time. This is meant to facilitate a military breakthrough for expelling Ukrainian forces from the entirety of Russia’s new regions, with any collapse of the front lines consequently paving the way for achieving additional military-political goals.

2. Coerce Ukraine Into Demilitarizing All Of Its Rump Regions East Of The Dnieper

Russia is unlikely to make territorial claims to Ukraine’s rump regions east of the Dnieper due to the high cost of sustainably securing, rebuilding, and integrating them, which is why it’ll probably instead demand their demilitarization as a buffer zone in exchange for letting Kiev retain political control. Any areas that it captures throughout the course of this reportedly launched campaign could be handed back upon that happening in a variation of the alleged compromises contained in spring 2022’s draft treaty.  

3. Deter NATO From Crossing The Dnieper If Member States’ Forces Conventionally Intervene

Russia doesn’t want NATO conventionally intervening in this conflict, but if member states like France and/or Poland unilaterally do so in the event that the front lines collapse, then Moscow hopes that its newly announced tactical nuclear weapons exercises will deter them from crossing the Dnieper. In connection with that, India and/or the Vatican could convey Russia’s red line to NATO, while Russia could restrain itself from chasing fleeing troops to and over the river so as to not worsen the security dilemma.

4. Influence Ukraine’s Possibly Impending US-Backed Regime Change Process

The Kremlin won’t negotiate with Zelensky, Poroshenko, or any of the other Ukrainian figures that were just placed on its Interior Ministry’s wanted list since it regards them as illegitimate so the US couldn’t freeze the conflict without someone else in power. Russia’s foreign intelligence service recently reported that the US is already exploring possible replacements to Zelensky, and Moscow naturally wants to influence this process in order to filter out figures who it knows wouldn’t abide by any peace agreement.

5. End The Conflict In A Way That Ensures Russia’s Core Security Interests In The New Reality

Russia’s maximalist goals of demilitarizing Ukraine, denazifying it, and restoring that country’s constitutional neutrality are unlikely to be achieved in full given the new reality of NATO preparing for a conventional intervention up to the Dnieper in order to avoid a strategic defeat in this proxy war. Considering that, Russia must resort to creative military-diplomatic means for ensuring its core security interests, though that requires an information campaign for tempering its supporters’ expectations.  

----------

As argued above, Russia’s fresh push into Kharkov Region is intended to end this conflict by year’s end in the best-case scenario, though that of course can’t be taken for granted given the fog of war and innumerable variables that the public isn’t privy to. Nevertheless, the five objectives that were enumerated in this piece encapsulate what it nowadays aims to achieve after over two years of intense proxy warfare with NATO, which might lead to some observers recalibrating their analyses.

https://www.zerohedge.com/geopolitical/heres-why-russias-making-fresh-push-ukraines-kharkov-region

Apple's Maryland store workers vote to authorize strike

 Workers at Apple's store in Towson, Maryland, have voted in favor of authorizing a strike, the International Association of Machinists and Aerospace Workers (AIM) said in a statement late on Saturday.

The date for work stoppage has yet to be decided, according to the union, which represents Apple's retail store workers in Maryland.

"The issues at the forefront of this action include concerns over work-life balance, unpredictable scheduling practices disrupting personal lives, and wages failing to align with the area's cost of living", IAM said in the statement.

"We will engage with the union representing our team in Towson respectfully and in good faith," an Apple spokeswoman said.

In June 2022, Apple workers at Maryland voted to join the International Association of Machinists and Aerospace Workers union, becoming the first retail employees of the tech giant to unionize in the United States.

Meanwhile, workers at Apple's store in Short Hills, New Jersey, voted against unionizing, Bloomberg News reported on Saturday.

Communications Workers of America (CWA), which filed complaints with the National Labour Relations Board (NLRB) alleging illegal union-busting by Apple at the New Jersey store and others, blamed the defeat on the company's behavior, the report said.

Apple retail staff at its New Jersey store had filed for union representation with Communications Workers of America on April 8, according to John Nagy, who is the operations lead at the Short Hills store and a member of the organizing committee

Apple did not respond to requests for comment on the vote against unionization. CWA and the NLRB did not immediately respond to a Reuters request for comment on the Bloomberg report on the New Jersey workers' vote.

https://sg.news.yahoo.com/apples-jersey-store-workers-vote-010457202.html

Trump again attacks New York prosecutor, floats economic plans at New Jersey rally

 Republican presidential candidate Donald Trump attacked the Manhattan judge and prosecutor in his New York criminal trial, while hinting at a range of possible economic policies at a sizable rally in New Jersey on Saturday.

Speaking before tens of thousands of supporters on a chilly beach on the Atlantic coastline, the former president disparaged District Attorney Alvin Bragg's appearance and dismissed the various state and federal charges he faces as a form of political persecution.

"Fat Alvin, corrupt guy," said Trump, who is on trial for allegedly falsifying business records to hide a hush money payment to a porn star before the 2016 presidential election that he won.

Trump also took aim at the trial judge, Justice Juan Merchan, accusing both men of working at the behest of President Joe Biden, his Democratic rival in this year's presidential rematch - an allegation for which there is no evidence.

"They're doing the bidding for crooked Joe Biden. This is all being done by crooked Joe Biden."

The New York case is one of four state and federal criminal trials Trump faces and may be the only one to be held before the Nov. 5 election. He has pleaded not guilty in all of them, portraying them as politically motivated.

Wildwood is less than 90 minutes from Pennsylvania, one of the nation's most competitive states, and it is a popular weekend spot for residents of metropolitan Philadelphia. Trump referred frequently to Pennsylvania during the rally.

He alluded to policies including a tax cut and fresh tariffs should he return to office.

Recounting a conversation with an unnamed automotive executive who had built factories in Mexico, Trump said he had pledged a 200% tariff on some imported cars. It was not clear what countries would be affected by the tariff or if his recounting of the conversation amounted to a formal policy proposal.

The Biden White House is itself poised to dramatically raise tariffs on Chinese electric vehicles in the coming days.

"I said, 'I will put a 200% tax on every car that comes in,'" Trump told the crowd.

Trump also said he would halt offshore wind projects in New Jersey and pledged to implement a new tax cut, without offering details.

Trump has come out in favor of extending a major tax cut that he signed to law in 2017, and Reuters reported in April that Trump was mulling an additional tax cut geared toward the middle class.

"Instead of a Biden tax hike, I'll give you a Trump middle-class, upper-class, lower-class, business-class big tax cut," he said.

Warming up the crowd was North Dakota Governor Doug Burgum, a one-time rival in the Republican primary race. The governor has since become a top contender to be Trump's vice-presidential candidate, according to multiple people who have talked to the former president. Trump appeared to allude to Burgum taking a major administration role in his speech.

"Get ready for something, OK?" Trump said, while discussing Burgum. "Just get ready."

https://www.marketscreener.com/news/latest/Trump-again-attacks-New-York-prosecutor-floats-economic-plans-at-New-Jersey-rally-46700888/